A fresh $58.0M Series A round is set to fuel RougeTx's mission to tackle diseases stemming from pericyte dysfunction. The biotech company announced the close of its latest funding, bringing in capital from a syndicate of investors.
RougeTx is developing first-in-class small-molecule therapies designed to restore vascular stability in conditions driven by pericyte dysfunction. The round saw participation from BGV (BioGeneration Ventures), Angelini Ventures, Aurea, Kurma Partners, Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures.
